Breaking News Instant updates and real-time market news.

CAT

Caterpillar

$88.92

0.7 (0.79%)

, CMI

Cummins

$130.84

2.67 (2.08%)

11:00
10/11/16
10/11
11:00
10/11/16
11:00

Goldman ups Caterpillar, Cummins to buy on upbeat margin outlook

The shares of Caterpillar (CAT) and engine maker Cummins (CMI) are climbing despite the down market after Goldman Sachs upgraded the stocks today. Both companies' margins should rise, wrote the firm, which also added Cummins to its Conviction List. CATERPILLAR: Caterpillar's margins should rise during the current cycle, enabling its earnings to reach $8 per share, wrote Goldman analyst Jerry Revich. The $8 EPS estimate is significantly above investors' expectations and the stock will rise significantly if Caterpillar is able to achieve that milestone, the analyst wrote. Moreover, the sentiment of both mutual funds and sell side analysts towards Caterpillar appears to be unenthusiastic, noted Revich, who estimated that the company's margins can reach 15%. Among the catalysts set to boost Caterpillar are increases in depressed mining equipment spending and the company's cost reductions, Revich wrote. He hiked his price target on the shares to $112 from $76. CUMMINS: Cummins' key end markets, including the U.S., the Chinese truck market, and mining and energy, "are approaching bottom," Revich believes. In China, the medium and heavy truck market bottomed in the first half of this year, the analyst reported. Meanwhile, new electronic logging regulations in the U.S. should lower truckers' overtime, reducing supply by 4% and eventually driving up truck prices, the analyst stated. Additionally, Cummins is taking several steps that will reduce its manufacturing costs, Revich believes. He raised his price target on the shares to $162 from $134. WHAT'S NOTABLE: In the same note, Revich downgraded Martin Marietta (MLM) and Summit Materials (SUM), both to Neutral from Buy, citing expectations for slowing growth in the fourth year of the construction recovery. Revich also downgraded KBR to (KBR) Sell from Neutral, citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. PRICE ACTION: In late morning trading, Caterpillar added 0.5% to $88.69 and Cummins gained 1.9% to $130.62 per share.

CAT

Caterpillar

$88.92

0.7 (0.79%)

CMI

Cummins

$130.84

2.67 (2.08%)

MLM

Martin Marietta

$169.86

-1.39 (-0.81%)

SUM

Summit Materials

$18.57

-0.42 (-2.21%)

KBR

KBR

$15.27

-0.9899 (-6.09%)

  • 25

    Oct

CAT Caterpillar
$88.92

0.7 (0.79%)

09/19/16
09/19/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PayPal (PYPL) downgraded to Hold from Buy at Canaccord with analyst Michael Graham saying he expects TPV growth to remain solid driven by Venmo and One Touch, but said these factors are well understood and reflected in estimates. 2. Viacom (VIA, VIAB) downgraded to Hold from Buy at Stifel with analyst Benjamin Mogil saying the stock's valuation is no longer attractive in the wake of the news that the company had decided to table its plans to sell a minority stake in Paramount. 3. Caterpillar (CAT) downgraded to Mixed from Positive at OTR Global with the firm saying third quarter global new heavy equipment orders are down 8%-11% year-over-year on weakness in North American. 4. Western Union (WU) downgraded to Negative from Neutral at Susquehanna with analyst James Friedman saying he is concerned about downside risks given the company's high multiple, increased regulatory scrutiny, and the lack of improvement in its Middle East business. 5. Campbell Soup (CPB) downgraded to Hold from Buy at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/19/16
OTRG
09/19/16
DOWNGRADE
OTRG
Mixed
Caterpillar downgraded to Mixed from Positive at OTR Global
OTR Global downgraded Caterpillar to Mixed saying Q3 global new heavy equipment orders are down 8-11% year-over-year on weakness in North American. The firm said EMEA North American used equipment availability is looser and dealers expect further used pricing pressures as large volumes of leased machines are returned to Caterpillar Financial.
10/11/16
GSCO
10/11/16
UPGRADE
Target $112
GSCO
Buy
Caterpillar upgraded to Buy from Neutral at Goldman
Goldman analyst Jerry Revich upgraded Caterpillar to Buy and raised its price target to $112 from $76 based on expectations for structurally higher margins in this cycle. The analyst believes stabilization in capex budgets suggest eventual normalization in mining equipment share of capex budgets. Following, the completion of the tier 4 product cycle, Revich said Caterpillar's R&D/sales is at 30+ year highs at 5.2% of sales, driving his view of flat to down R&D spending in a recovery, which is a 5% tailwind to incremental margins. The analyst sees $8 in mid-cycle earnings, well ahead of investor expectations, and said mutual funds are broadly underweight Caterpillar shares.
10/11/16
10/11/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Hold from Sell at Evercore ISI with analyst Ken Sena citing the recent pullback in the shares. 2. Tyson Foods (TSN) upgraded to Outperform from Market Perform at BMO Capital with analyst Kenneth Zaslow saying he thinks that the company's "strong underlying fundamentals" should enable its fiscal 2017 profits to beat expectations, and he says that the shares are undervalued. 3. Virgin America (VA) upgraded to Neutral from Underweight at JPMorgan with analyst Jamie Baker saying regulatory approval of the pending Alaska Air (ALK) takeover "remains more likely than not." 4. Cummins (CMI) was upgraded to Conviction Buy from Neutral and Caterpillar (CAT) was upgraded to Buy from Neutral at Goldman. 5. Carbonite (CARB) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Schwartz saying he sees "substantial upside" from current levels due to valuation and fundamentals. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CMI Cummins
$130.84

2.67 (2.08%)

10/11/16
GSCO
10/11/16
UPGRADE
Target $162
GSCO
Conviction Buy
Cummins upgraded to Conviction Buy from Neutral at Goldman
Goldman analyst Jerry Revich upgraded CMI to Conviction Buy from Neutral saying he expects structurally higher margins in this cycle. The analyst said key end markets are bottoming, margins are well above prior cycle trough, and sees further upside to margin expectations driven by the Power Systems restructuring. Revich raised Cummins' price target to $162 from $134 based on mid-cycle valuation and the catalyst of new electronic logging standards that suggest potential US and international truck demand should begin to normalize.
09/07/16
09/07/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Navistar (NAV) initiated with a Hold at Deutsche Bank. 2. Barrick Gold (ABX) initiated with a Sell at Berenberg while the firm initiated Randgold (GOLD), Kinross Gold (KGC), and Goldcorp (GG) with a Hold. 3. 3. After the close on Tuesday, Deutsche Bank analysts Nicole DeBlase, Saree Boroditsky, and Kevin Marek initiated the U.S. Machinery group with a "cautious view." Oshkosh (OSK), Caterpillar (CAT), and Wabtec (WAB) were initiated with Buy ratings at Deutsche Bank, while the firm initiated Cummins (CMI) and CNH Industrial (CNHI) with Sell ratings. The firm also initiated Deere (DE), AGCO (AGCO), Terex (TEX), PACCAR (PCAR), WABCO (WBC), and United Rentals (URI) with Hold ratings. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/30/16
LYON
09/30/16
INITIATION
Target $150
LYON
Buy
Cummins initiated with a Buy at CLSA
CLSA analyst Kristine Kubacki initiated Cummins with a Buy and a $150 price target. The analyst Cummins is nearing deep trough levels in many of its end markets and expects a recovery in major North American and industrial end markets in 2018.
MLM Martin Marietta
$169.86

-1.39 (-0.81%)

02/10/16
VERT
02/10/16
UPGRADE
VERT
Buy
Martin Marietta upgraded to Buy from Hold at Vertical Research
10/11/16
GSCO
10/11/16
DOWNGRADE
GSCO
Neutral
Martin Marietta downgraded to Neutral from Buy at Goldman
Goldman analyst Jerry Revich downgraded Martin Marietta to Neutral citing valuation and expectations for slowing growth in the 4th year of the construction recovery. The analyst said the US public construction recovery is slowing and private non-residential construction is slowing as chemicals and LNG peak. The analyst lowered his price target to $202 from $210 on Martin Marietta shares.
05/09/16
SPHN
05/09/16
NO CHANGE
Target $200
SPHN
Overweight
Martin Marietta price target raised to $200 from $179 at Stephens
Stephens analyst Trey Grooms raised his price target for Martin Marietta to $200 from $179 following the company's "strong" Q1 results, coming in ahead of expectations in every category. The analyst reiterates an Overweight rating on the shares.
05/09/16
05/09/16
NO CHANGE

Martin Marietta Q1 results 'impressive,' says Sterne Agee CRT
Sterne Agee CRT believes that Martin Marietta reported "impressive" Q1 results, and it says the company's comments were "positive." Sterne says it's "more fired up about the medium-term outlook for the aggregates industry than" it's been in a decade. The firm raised its price target on the name to $202 from $192 and keeps a Buy rating on the shares.
SUM Summit Materials
$18.57

-0.42 (-2.21%)

02/17/16
SBSH
02/17/16
UPGRADE
Target $21
SBSH
Buy
Summit Materials upgraded to Buy from Neutral at Citi
Citi analyst Scott Schrier upgraded Summit Materials to Buy citing an attractive valuation and a "constructive outlook" for the heavy materials space. The analyst has a $21 price target for the shares.
02/17/16
02/17/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ocular Therapeutix (OCUL) upgraded to Overweight at Morgan Stanley by analyst Andrew Berens, who said the company's management provided a pathway forward for OTX-TP in glaucoma that appears to be a much lower bar than expected. 2. Carlyle Group (CG) upgraded to Overweight at Morgan Stanley, with analyst Michael Cyprys citing compelling risk/reward and near-term catalysts that include the $4B in portfolio exit pipeline, a $4B investment deployment pipeline, a $200M buyback program, cost controls, and focus on more scalable fund strategies. 3. Tyson Foods (TSN) upgraded to Overweight by Stephens analyst Farha Aslam, who said its valuation multiple should move up since its earnings growth and stability, balance sheet and product portfolio are mirroring that of consumer packaged food companies. 4. Tyler Technologies (TYL) upgraded to Buy at B. Riley, with analyst Kevin Liu citing the New World Systems (NWS) acquisition and expects results and guidance to compare favorably to his estimates. 5. Summit Materials (SUM) upgraded to Buy at Citi by analyst Scott Schrier, who cited attractive valuation and a "constructive outlook" for the heavy materials space. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/01/16
RBCM
04/01/16
NO CHANGE
RBCM
Summit Materials price target raised to $23 from $18 at RBC Capital
After meeting with Summit's CFO, RBC Capital thinks that the stock can rise based on what it sees as potential improving price/volume trends, margin expansion, and strategic M&A. RBC keeps an Outperform rating on the shares.
10/11/16
GSCO
10/11/16
DOWNGRADE
GSCO
Neutral
Summit Materials downgraded to Neutral from Buy at Goldman
Goldman analyst Jerry Revich downgraded Summit Materials to Neutral based on expectations for slowing growth in the 4th year of the construction recovery. The analyst lowered his price target to $21 from $22 on Summit shares.
KBR KBR
$15.27

-0.9899 (-6.09%)

10/11/16
GSCO
10/11/16
DOWNGRADE
Target $15
GSCO
Sell
KBR downgraded to Sell from Neutral at Goldman
Goldman analyst Jerry Revich downgraded KBR to Sell citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. The analyst lowered his price target to $15 from $16.
10/05/16
10/05/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UBS (UBS) upgraded to Sector Perform from Underperform at RBC Capital with analyst Fiona Swaffield saying she sees a dividend reduction as unlikely and believes expectations for the bank's Wealth Management business are now lower. 2. Parker-Hannifin (PH) upgraded to Buy from Hold at Stifel with analyst Nathan Jones saying distributors expect to see revenue growth declining 2% in the second quarter of fiscal 2017 which he believes should be enough for Parker to see its first positive year-over-year revenue comp company wide in six quarters. 3. Flex (FLEX) upgraded to Conviction Buy from Buy at Goldman with analyst Mark Delaney saying it is positioned to benefit from entry into new markets and valuation looks attractive. 4. KBR (KBR) upgraded to Accumulate from Hold at Johnson Rice with analyst Martin Malloy citing the recent pullback in shares and said the stock multiple should trend higher given the shift in business mix to more low-risk, cost reimbursement revenues. 5. Plains All American (PAA) upgraded to Outperform from Market Perform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/05/16
JRCO
10/05/16
UPGRADE
Target $18
JRCO
Accumulate
KBR upgraded to Accumulate from Hold at Johnson Rice
Johnson Rice analyst Martin Malloy upgraded KBR to Accumulate with an $18 price target citing the recent pullback in shares and said the stock multiple should trend higher given the shift in business mix to more low-risk, cost reimbursement revenues.
10/11/16
10/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comerica (CMA) downgraded to Market Perform from Outperform at FBR Capital with analyst Bob Ramsey citing valuation following the recent strength in the shares. 2. Charter downgraded to Neutral from Buy at MoffettNathanson with analyst Craig Moffett saying shares have risen sharply year-to-date, along with consensus estimates, and views shares as fairly valued. 3. BHP Billiton (BHP) downgraded to Neutral from Buy at UBS with the firm citing its expectations for lower iron ore and coal prices over the next six months. 4. Illumina (ILMN) downgraded to Sell from Neutral at Janney Capital and to Neutral from Buy at Citi. 5. KBR (KBR) downgraded to Sell from Neutral at Goldman with analyst Jerry Revich citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

CORI

Corium

$10.88

0.03 (0.28%)

07:10
09/26/17
09/26
07:10
09/26/17
07:10
Initiation
Corium initiated  »

Corium initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

FDS

FactSet

$170.81

2.2 (1.30%)

07:10
09/26/17
09/26
07:10
09/26/17
07:10
Earnings
FactSet reports Q4 adj. EPS $1.90, consensus $1.89 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

LNG

Cheniere Energy

$44.12

0.64 (1.47%)

07:09
09/26/17
09/26
07:09
09/26/17
07:09
Initiation
Cheniere Energy initiated  »

Cheniere Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHK

Chesapeake

$4.37

0.15 (3.55%)

07:09
09/26/17
09/26
07:09
09/26/17
07:09
Hot Stocks
Chesapeake sees Q3 production 542,000 boe per day »

Chesapeake Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 02

    Oct

KTOS

Kratos Defense

$12.72

-0.28 (-2.15%)

07:08
09/26/17
09/26
07:08
09/26/17
07:08
Hot Stocks
Kratos Defense receives $9.7M in contract awards »

Kratos Defense announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVGN

Evogene

$4.54

0.23 (5.34%)

07:08
09/26/17
09/26
07:08
09/26/17
07:08
Hot Stocks
Evogene reports 'positive' results in 2nd year field trials in banana »

Evogene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
Axovant Phase 3 Alzheimer's study misses co-primary endpoints »

Axovant Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AST

Asterias

$3.25

0.05 (1.56%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
Asterias receives regulatory clearance to start AST-VAC2 clinical trial »

Asterias Biotherapeutics,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MDXG

MiMedx

$12.35

-0.28 (-2.22%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
MiMedx announces confidential lawsuit settlement with terminated employee »

MiMedx Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 13

    Nov

  • 14

    Nov

DRI

Darden

$83.14

0.26 (0.31%)

07:06
09/26/17
09/26
07:06
09/26/17
07:06
Hot Stocks
Darden reports Q1 Olive Garden same-restaurant sales up 1.9% »

Reports Q1 same…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AGN

Allergan

$211.61

6.96 (3.40%)

07:05
09/26/17
09/26
07:05
09/26/17
07:05
Recommendations
Allergan analyst commentary  »

Allergan weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZRE

Azure Power

$16.18

0.18 (1.13%)

07:05
09/26/17
09/26
07:05
09/26/17
07:05
Hot Stocks
Azure Power awarded 260 MW solar project in Gujarat »

Azure Power announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEES

H&E Equipment

$26.97

-0.2 (-0.74%)

07:04
09/26/17
09/26
07:04
09/26/17
07:04
Initiation
H&E Equipment initiated  »

H&E Equipment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOG

Northern Oil and Gas

$0.94

0.093 (10.98%)

07:04
09/26/17
09/26
07:04
09/26/17
07:04
Hot Stocks
Northern Oil and Gas announces settlement with former CEO »

Northern Oil and Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$83.14

0.26 (0.31%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Breaking Hot Stocks news story on Darden »

Darden reports Q1 Olive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BTX

BioTime

$2.72

-0.08 (-2.86%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
BioTime announces 'positive' secondary, long-term data from Renevia trial »

BioTime announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MBRX

Moleculin Biotech

$2.41

-0.07 (-2.82%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Moleculin Biotech announces FDA approval of Annamycin IND »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNCA

Genocea

$5.33

0.04 (0.76%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Downgrade
Genocea rating change  »

Genocea downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

DRI

Darden

$83.14

0.26 (0.31%)

07:03
09/26/17
09/26
07:03
09/26/17
07:03
Hot Stocks
Darden reports Q1 blended same-restaurant sales from legacy brands up 1.7% »

Q1 same-restaurant sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Akebia »

Akebia: Phase 2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Axovant Sciences »

Axovant announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$83.14

0.26 (0.31%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Earnings
Darden backs FY18 adjusted cont ops EPS view $4.38-$4.50, consensus $4.47 »

The company reaffirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:02
09/26/17
09/26
07:02
09/26/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Akebia »

Akebia: Phase 3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AKBA

Akebia

$17.90

0.33 (1.88%)

07:01
09/26/17
09/26
07:01
09/26/17
07:01
Hot Stocks
Akebia saya Phase 2 vadadustat study confirmed findings from previous studies »

Akebia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

07:00
09/26/17
09/26
07:00
09/26/17
07:00
General news
FX Update: The dollar has been in rally mode »

FX Update: The dollar has…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.